Cargando…

Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-κB and beta-catenin pathways

Treatment of oral cancer is based exclusively on surgery combined with or without chemotherapy. However, it has several side effects. Targeting a new, more effective therapy has become an urgent matter. The purpose of this study was to evaluate the anti-tumor activity of rapamycin in oral cancer and...

Descripción completa

Detalles Bibliográficos
Autores principales: Semlali, Abdelhabib, Papadakos, Sofia, Contant, Camille, Zouaoui, Ikram, Rouabhia, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520465/
https://www.ncbi.nlm.nih.gov/pubmed/36185289
http://dx.doi.org/10.3389/fonc.2022.873447
_version_ 1784799630603583488
author Semlali, Abdelhabib
Papadakos, Sofia
Contant, Camille
Zouaoui, Ikram
Rouabhia, Mahmoud
author_facet Semlali, Abdelhabib
Papadakos, Sofia
Contant, Camille
Zouaoui, Ikram
Rouabhia, Mahmoud
author_sort Semlali, Abdelhabib
collection PubMed
description Treatment of oral cancer is based exclusively on surgery combined with or without chemotherapy. However, it has several side effects. Targeting a new, more effective therapy has become an urgent matter. The purpose of this study was to evaluate the anti-tumor activity of rapamycin in oral cancer and its mechanism of action. Human gingival carcinoma cells were stimulated with different concentrations of rapamycin to assess proliferation, colony formation, cell migration, as well as apoptosis, and autophagy. The expression of proteins involved in the cell cycle (cyclin D1, p15, p21, p27) and autophagy, as well as that of oncogenes and tumor suppressor genes, were determined by quantitative PCR. The signaling pathways were evaluated by Western blotting. Our results show that rapamycin has a selective effect at a low dose on cancer cell growth/survival. This was confirmed by low colony formation and the inhibition of cell migration, while increasing cell apoptosis by activating caspase-9 and -3. Rapamycin promoted cell autophagy and increased mitochondrial oxidative stress by being involved in DNA damage in the exposed cells. Finally, rapamycin exhibits potent anti-oral cancer properties through inhibition of several cancer-promoting pathways (MAPK, NF-κB, and Wnt/beta-catenin). These results indicate that rapamycin could be a potential agent for the treatment of oral cancer and for a prevention strategy.
format Online
Article
Text
id pubmed-9520465
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95204652022-09-30 Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-κB and beta-catenin pathways Semlali, Abdelhabib Papadakos, Sofia Contant, Camille Zouaoui, Ikram Rouabhia, Mahmoud Front Oncol Oncology Treatment of oral cancer is based exclusively on surgery combined with or without chemotherapy. However, it has several side effects. Targeting a new, more effective therapy has become an urgent matter. The purpose of this study was to evaluate the anti-tumor activity of rapamycin in oral cancer and its mechanism of action. Human gingival carcinoma cells were stimulated with different concentrations of rapamycin to assess proliferation, colony formation, cell migration, as well as apoptosis, and autophagy. The expression of proteins involved in the cell cycle (cyclin D1, p15, p21, p27) and autophagy, as well as that of oncogenes and tumor suppressor genes, were determined by quantitative PCR. The signaling pathways were evaluated by Western blotting. Our results show that rapamycin has a selective effect at a low dose on cancer cell growth/survival. This was confirmed by low colony formation and the inhibition of cell migration, while increasing cell apoptosis by activating caspase-9 and -3. Rapamycin promoted cell autophagy and increased mitochondrial oxidative stress by being involved in DNA damage in the exposed cells. Finally, rapamycin exhibits potent anti-oral cancer properties through inhibition of several cancer-promoting pathways (MAPK, NF-κB, and Wnt/beta-catenin). These results indicate that rapamycin could be a potential agent for the treatment of oral cancer and for a prevention strategy. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9520465/ /pubmed/36185289 http://dx.doi.org/10.3389/fonc.2022.873447 Text en Copyright © 2022 Semlali, Papadakos, Contant, Zouaoui and Rouabhia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Semlali, Abdelhabib
Papadakos, Sofia
Contant, Camille
Zouaoui, Ikram
Rouabhia, Mahmoud
Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-κB and beta-catenin pathways
title Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-κB and beta-catenin pathways
title_full Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-κB and beta-catenin pathways
title_fullStr Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-κB and beta-catenin pathways
title_full_unstemmed Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-κB and beta-catenin pathways
title_short Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-κB and beta-catenin pathways
title_sort rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing erk1/2, nf-κb and beta-catenin pathways
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520465/
https://www.ncbi.nlm.nih.gov/pubmed/36185289
http://dx.doi.org/10.3389/fonc.2022.873447
work_keys_str_mv AT semlaliabdelhabib rapamycininhibitsoralcancercellgrowthbypromotingoxidativestressandsuppressingerk12nfkbandbetacateninpathways
AT papadakossofia rapamycininhibitsoralcancercellgrowthbypromotingoxidativestressandsuppressingerk12nfkbandbetacateninpathways
AT contantcamille rapamycininhibitsoralcancercellgrowthbypromotingoxidativestressandsuppressingerk12nfkbandbetacateninpathways
AT zouaouiikram rapamycininhibitsoralcancercellgrowthbypromotingoxidativestressandsuppressingerk12nfkbandbetacateninpathways
AT rouabhiamahmoud rapamycininhibitsoralcancercellgrowthbypromotingoxidativestressandsuppressingerk12nfkbandbetacateninpathways